Is NiceRx an Inmazeb coupon provider?
We are a service provider that helps eligible individuals access the Inmazeb patient assistance program. That means that we do not offer printable Inmazeb manufacturer coupons, Inmazeb discounts, or free Inmazeb samples. We are not an Inmazeb coupon provider or an Inmazeb discount card. Our service extends to assisting eligible individuals to access the medications they need through patient assistance programs.
Inmazeb patient assistance program
Patient assistance programs are typically sponsored by pharmaceutical companies and provide free or discounted medications to individuals with low income who are uninsured or under-insured and meet the eligibility criteria that vary by program. There are currently no known patient assistance programs for this medication.
Can NiceRx help me get Inmazeb cheaper if I have insurance?
How much does Inmazeb cost without insurance?
Inmazeb cost without insurance will vary depending on where you buy it. With NiceRx you will pay a flat monthly fee of $49, regardless of the retail price of your medication.
How much does Inmazeb cost with insurance?
The copay for Inmazeb with insurance depends on the terms of your healthcare plan. To find out how much this is, your healthcare provider or pharmacist will be able to calculate your copay with your current insurance.
What is Inmazeb?
Inmazeb is the first FDA-approved (U.S. Food and Drug Administration) treatment for the Ebola virus disease. It is manufactured by Regeneron Pharmaceuticals, Inc. It is a combination of Zaire ebolavirus glycoprotein-directed human monoclonal antibodies (atoltivimab, maftivimab, and odesivimab), used to treat infections caused by Zaire ebolavirus in adults and pediatric patients, including neonates born to mothers who are RT-PCR positive for Zaire ebolavirus infection. Zaire ebolavirus can mutate and the emergence of resistance or changes in viral severity could reduce the effects of antiviral drugs for Ebola treatment over time.
FDA approval of Inzameb was based on two clinical trials. Inmazeb was evaluated in patients with the Ebola infectious disease in the PALM trial (PAmoja tuLinde Maisha) and as part of an expanded access program conducted in the Democratic Republic of the Congo (DRC) during an Ebola outbreak. The PALM trial was led by the U.S. National Institutes of Health and the DRC’s Institut National de Recherche Biomédicale.
In the PALM trial, the safety and efficacy of Inmazeb were evaluated in a controlled trial, in which 154 patients received Inmazeb as a single infusion, and 168 patients received an investigational control. The primary efficacy endpoint was 28-day mortality. Of the 154 patients who received Inmazeb, almost 34% died after 28 days, compared to 51% of the 153 patients who received a control.
What doses of Inmazeb are available?
Inmazeb is available in injection form, in the following doses: 241.7 mg of atoltivimab, 241.7 mg of maftivimab, and 241.7 mg of odesivimab per 14.5 mL in a single-dose vial.
Always speak with your healthcare provider about any changes to your dose so they can monitor and evaluate your condition.
Inmazeb active ingredients
Inmazeb contains atoltivimab, maftivimab, and odesivimab-ebgn as the active ingredients. Inmazeb targets the glycoprotein on the surface of the Ebola virus. Glycoproteins attach to the cell receptor and fuse the virus and host cell membranes together, allowing the virus to enter the cell. The three antibodies contained in Inmazeb bind to this glycoprotein blocking attachment and entry of the virus.
Inmazeb side effects
The most common side effects of Inmazeb in clinical trials include:
In rare instances, Inmazeb can cause more serious side effects. These can include:
- Hypersensitivity reactions including life-threatening infusion-associated events
Your doctor will assess the benefits of using Inmazeb against your risk of side effects. Patients are encouraged to report negative side effects or adverse reactions of Inmazeb to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.
Inmazeb drug interactions
Inmazeb can interact with other medications. These include:
- Inmazeb may reduce the effectiveness of the live vaccine
This list is not exhaustive and other prescription drugs may interact with Inmazeb.
You should not use Inmazeb if you:
- Are allergic to the active ingredients atoltivimab, maftivimab, or odesivimab-ebgn
- Are allergic to any of the other ingredients in Inmazeb
- Are breastfeeding or are planning to breastfeed
Talk to your doctor before using Inmazeb if you:
- Are taking any of the medications that could interact with Inmazeb
- Are pregnant or are planning to become pregnant
Inmazeb is the trademark brand name for atoltivimab, maftivimab, and odesivimab-ebgn manufactured by Regeneron Pharmaceuticals, Inc. A generic version of atoltivimab, maftivimab, and odesivimab-ebgn is not available. Generic drugs are generally cheaper than brand-name drugs, but you can still find Inmazeb savings through NiceRx.
The content on this website is intended for information purposes only. It does not constitute medical advice. The information on this website should not be relied upon and is not a substitute for professional medical advice. You should always speak to your doctor regarding the risks and benefits of any treatment.